Not likely to be adjunct disease trials.
The efficacy of blarcamesine against SARS-Cov-2 (the virus) and COVID-19 (the disease) won’t be demonstrated in deliberate human clinical trials. Same for the other very positive therapeutic outcomes produced by the molecule, such as suppression of insomnia, antineoplastic outcomes (anti-cancer), cardiovascular system improvements, etc. All of that would be expensive and very time-consuming.
Instead, get the drug approved for two big CNS diseases, Parkinson’s disease dementia and Alzheimer’s, then let the millions suffering from those CNS diseases start taking blarcamesine. Then, simply tally (statistically assess) the occurrence of those other diseases in people taking blarcamesine, compared to statistically-valid parallel groups not taking the drug. What happens when it is discovered that people taking blarcamesine get degrees of relief for the CNS diseases targeted for them, but at the same time other positive health benefits appear? People on the drug sleep healthfully; no insomnia. COVID-19 cases are fewer and/or less severe.
Detailed analyses of people taking blarcamesine for CNS diseases will reveal other associated, commensurate positive outcomes — which will obviously occur in people taking blarcamesine without any CNS condition.
Market Data 
Markets 
AI
